Codexis Announces Appointment of Margaret Fitzgerald as Chief Legal Officer and General Counsel
November 01 2022 - 8:00AM
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company
enabling the promise of synthetic biology, today announced the
appointment of Margaret (“Meg”) Fitzgerald as Chief Legal Officer
and General Counsel, effective immediately. In this role, Ms.
Fitzgerald will lead the Company’s legal and compliance functions
and provide strategic guidance to the Board of Directors and
executive management team. She will report directly to Dr. Stephen
Dilly, President and CEO of Codexis.
“Meg is a seasoned legal executive and leader
with extensive experience on both routine and complex legal
matters,” said Dr. Dilly. “Meg brings invaluable legal and business
expertise across product development, commercial launches,
compliance, and intellectual property. I am excited to welcome Meg
to the team. Meg’s skill set will prove critical as we continue to
grow our business.”
“I am delighted to join Codexis at this exciting
time in the Company’s development and I look forward to building
upon the team’s many accomplishments,” said Ms. Fitzgerald.
“Codexis is a leader in the enzyme engineering space, and I am
honored to work alongside this talented executive team as we
continue delivering meaningful innovations across our core target
markets.”
Ms. Fitzgerald brings over twenty years of
experience across the biotechnology industry. Most recently, she
served as General Counsel, Corporate Secretary and Chief Compliance
Officer at Allakos, Inc., where she provided strategic legal advice
on securities, litigation, IP strategy, clinical development, and
commercialization. Prior to Allakos, Ms. Fitzgerald was Associate
General Counsel and Privacy Officer at Aimmune Therapeutics, Inc.
Previously, she served as Vice President of Corporate Law at ZS
Pharma, Inc., where she chaired negotiations, resulting in the $2.7
billion sale of ZS Pharma to AstraZeneca. Earlier in her career,
Ms. Fitzgerald held increasingly senior leadership roles at
Genentech, Inc., ultimately serving as Associate General Counsel
and Director of Transactional Law. Ms. Fitzgerald also served as an
Associate Attorney at Pillsbury Winthrop Shaw Pittman. She holds a
J.D. from University of California, Berkeley, as well as an M.A.
and a B.A. in History from Stanford University.
About Codexis
Codexis is a leading enzyme engineering company
leveraging its proprietary CodeEvolver® platform to discover and
develop novel, high performance enzymes and biotherapeutics.
Codexis enzymes have applications in the sustainable manufacturing
of pharmaceuticals, food, and industrial products; in the creation
of the next generation of life science tools; and as gene therapy
and oral enzyme therapies. The Company’s unique performance enzymes
drive improvements such as: reduced energy usage, waste generation
and capital requirements; higher yields; higher fidelity
diagnostics; and more efficacious therapeutics. Codexis enzymes
enable the promise of synthetic biology to improve the health of
people and the planet. For more information, visit
www.codexis.com.
Forward-Looking Statements
To the extent that statements contained in this press release
are not descriptions of historical facts regarding Codexis, they
are forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
You should not place undue reliance on these forward-looking
statements because they involve known and unknown risks,
uncertainties and other factors that are, in some cases, beyond
Codexis’ control and that could materially affect actual results.
Additional information about factors that could materially affect
actual results can be found in Codexis’ Annual Report on Form 10-K
filed with the Securities and Exchange Commission (“SEC”) on
February 28, 2022 and in Codexis’ Quarterly Report on Form 10-Q
filed with the SEC on August 5, 2022, including under the caption
“Risk Factors,” and in Codexis’ other periodic reports filed with
the SEC. Codexis expressly disclaims any intent or obligation to
update these forward-looking statements, except as required by
law.
Investor Relations Contact:
Argot PartnersBrendan Strong/Carrie McKim(212)
600-1902Codexis@argotpartners.com
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Jul 2023 to Jul 2024